Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Soleno Therapeutics Inc
SLNO49.550USD
-0.220-0.44%
Close 11/26, 16:00（ET）Quotes delayed by 15 min
2.26BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Soleno Therapeutics Inc
Currency: USD Updated: 2025-11-26Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Soleno Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
13
analysts
Buy
Current Rating
113.538
Target Price
+129.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Soleno Therapeutics Inc Highlights
StrengthsRisks
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -28.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.51M shares, decreasing 5.04% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 8.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.73.
Financial Health
Currency: USD Updated: 2025-11-26The company's current financial score is 9.06, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high.
Score
Financials
8.38
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
9.33
Shareholder Returns
7.58
Soleno Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-11-26The company’s current valuation score is 6.81, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -28.38, which is -97.74% below the recent high of -0.64 and -3.32% above the recent low of -29.32.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 36/405
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-11-26The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.02. The average price target for Soleno Therapeutics Inc is 110.00, with a high of 145.00 and a low of 75.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
113.538
Target Price
+129.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
523
Total
6
Median
6
Average
Company name
Ratings
Analysts
Soleno Therapeutics Inc
SLNO
13
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
1
2
3
...
105
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-26The company’s current price momentum score is 7.18, which is equal to the Biotechnology & Medical Research industry's average of 7.18. Sideways: Currently, the stock price is trading between the resistance level at 67.63 and the support level at 36.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
Institutional Confidence
Currency: USD Updated: 2025-11-26The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.14. The latest institutional shareholding proportion is 108.94%, representing a quarter-over-quarter decrease of 1.36%. The largest institutional shareholder is PRFDX, holding a total of 3.85M shares, representing 7.16% of shares outstanding, with 104.73% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
Janus Henderson Investors
BlackRock Institutional Trust Company, N.A.
Avoro Capital Advisors LLC
Wellington Management Company, LLP
Vivo Capital, LLC
State Street Investment Management (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-11-26The company’s current risk assessment score is 3.62, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -3.06. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
-3.10
VaR
+6.72%
240-Day Maximum Drawdown
+50.80%
240-Day Volatility
+76.36%
Return
Best Daily Return
60 days
+13.46%
120 days
+13.46%
5 years
+504.97%
Worst Daily Return
60 days
-26.59%
120 days
-26.59%
5 years
-48.70%
Sharpe Ratio
60 days
-0.84
120 days
-0.80
5 years
+0.44
Risk Assessment
Maximum Drawdown
240 days
+50.80%
3 years
+50.80%
5 years
+98.04%
Return-to-Drawdown Ratio
240 days
+0.10
3 years
+13.01
5 years
+0.03
Skewness
240 days
+1.34
3 years
+24.45
5 years
+27.79
Volatility
Realised Volatility
240 days
+76.36%
5 years
+125.99%
Standardised True Range
240 days
+6.87%
5 years
+3.31%
Downside Risk-Adjusted Return
120 days
-93.09%
240 days
-93.09%
Maximum Daily Upside Volatility
60 days
+73.70%
Maximum Daily Downside Volatility
60 days
+92.67%
Liquidity
Average Turnover Rate
60 days
+2.83%
120 days
+2.88%
5 years
--
Turnover Deviation
20 days
+73.43%
60 days
+49.07%
120 days
+52.13%
Peer Comparison
Biotechnology & Medical Research
Soleno Therapeutics Inc
SLNO
7.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zymeworks Inc
ZYME
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
NewAmsterdam Pharma Company NV
NAMS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Soleno Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Soleno Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Soleno Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Soleno Therapeutics Inc?
To generate the financial health score of Soleno Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Soleno Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Soleno Therapeutics Inc.
How do we generate the company valuation score of Soleno Therapeutics Inc?
To generate the company valuation score of Soleno Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Soleno Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Soleno Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Soleno Therapeutics Inc.
How do we generate the earnings forecast score of Soleno Therapeutics Inc?
To calculate the earnings forecast score of Soleno Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Soleno Therapeutics Inc’s future.
How do we generate the price momentum score of Soleno Therapeutics Inc?
When generating the price momentum score for Soleno Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Soleno Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Soleno Therapeutics Inc.
How do we generate the institutional confidence score of Soleno Therapeutics Inc?
To generate the institutional confidence score of Soleno Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Soleno Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Soleno Therapeutics Inc.
How do we generate the risk management score of Soleno Therapeutics Inc?
To assess the risk management score of Soleno Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Soleno Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Soleno Therapeutics Inc.
